Open Label Study to Evaluate the Safety Profile and the Quality of Life in Patients Receiving Etanercept for the Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2011

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary)
Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
Focus Adverse reactions
Sponsors Wyeth

Most Recent Events

23 Sep 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
23 Sep 2010 Planned end date changed from 1 Sep 2011 to 1 Jul 2010 as reported by ClinicalTrials.gov.
24 Mar 2010 Planned number of patients changed from 1000 to 909 as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight